PE20081687A1 - Proteina de fusion - Google Patents
Proteina de fusionInfo
- Publication number
- PE20081687A1 PE20081687A1 PE2008000128A PE2008000128A PE20081687A1 PE 20081687 A1 PE20081687 A1 PE 20081687A1 PE 2008000128 A PE2008000128 A PE 2008000128A PE 2008000128 A PE2008000128 A PE 2008000128A PE 20081687 A1 PE20081687 A1 PE 20081687A1
- Authority
- PE
- Peru
- Prior art keywords
- joined
- fusion protein
- same
- fragment
- epitops
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 abstract 2
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 abstract 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 abstract 2
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N Histidine Chemical compound OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
SE REFIERE A UN ANTICUERPO HUMANIZADO O PROTEINA DE FUSION, LA CUAL COMPRENDE: A) NY-ESO-1 O UN FRAGMENTO QUE INCLUYA UNO O MAS EPITOPOS DEL MISMO Y SU EXTREMO C SE UNA A LAGE-1; B) LAGE-1 O UN FRAGMENTO QUE INCLUYA UNO O MAS EPITOPOS DEL MISMO Y SU EXTREMO N SE UNE A NY-ESO-1; C) UN COMPONENTE DE FUSION HETEROLOGO, TAL COMO LA PROTEINA D O UN FRAGMENTO REPRESENTADO POR LOS AMINOACIDOS 20 A 127 DE LA MISMA, CUYA PORCION N SE UNE CON LOS AMINOACIDOS Met, Asp Y Pro; D) UNA MARCA DE AFINIDAD, TAL COMO HISTIDINA. TAMBIEN SE REFIERE AL AMINOACIDO CODIFICADOR, VECTOR, CELULA HUESPED, PROCEDIMIENTO DE PREPARACION Y ADICIONALMENTE UN ADYUVANTE O QUIMIOCINA PARA DAR UNA COMPOSICION INMUNOGENICA. DICHA PROTEINA DE FUSION INDUCE RESPUESTA INMUNE CONTRA CELULAS CANCERIGENAS
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0700759A GB0700759D0 (en) | 2007-01-15 | 2007-01-15 | Novel fusion protein |
US91492507P | 2007-04-30 | 2007-04-30 | |
US91484807P | 2007-04-30 | 2007-04-30 | |
GB0709707A GB0709707D0 (en) | 2007-05-21 | 2007-05-21 | Novel fusion protein |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081687A1 true PE20081687A1 (es) | 2008-12-25 |
Family
ID=41111108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000128A PE20081687A1 (es) | 2007-01-15 | 2008-01-11 | Proteina de fusion |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2118128B1 (es) |
JP (1) | JP2010532656A (es) |
KR (1) | KR20090122426A (es) |
BR (1) | BRPI0806501A2 (es) |
CA (1) | CA2674458A1 (es) |
DK (1) | DK2118128T3 (es) |
EA (1) | EA016818B1 (es) |
ES (1) | ES2398492T3 (es) |
HR (1) | HRP20130022T1 (es) |
MX (1) | MX2009007572A (es) |
PE (1) | PE20081687A1 (es) |
PL (1) | PL2118128T3 (es) |
SI (1) | SI2118128T1 (es) |
TW (1) | TW200902049A (es) |
WO (1) | WO2008089074A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008308474A (ja) * | 2007-06-18 | 2008-12-25 | Nitto Denko Corp | 抗原ペプチド製剤の調製方法 |
BRPI1009873A2 (pt) | 2009-03-17 | 2016-03-08 | Glaxosmithkline Biolog Sa | detecção aperfeiçoada de expressão gênica |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
AU2012302778B2 (en) * | 2011-08-31 | 2016-11-24 | Mie University | Vaccine preparation for cancer treatment |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
JP6659535B2 (ja) | 2013-06-28 | 2020-03-04 | オークランド ユニサービシーズ リミティド | アミノ酸及びペプチド接合体及び接合方法 |
WO2015050158A1 (ja) | 2013-10-01 | 2015-04-09 | 国立大学法人三重大学 | 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン |
CA2971677A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
BR112018017174A2 (pt) | 2016-02-26 | 2019-01-02 | Auckland Uniservices Ltd | conjugados de aminoácido e peptídeo e processo de conjugação |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06205672A (ja) * | 1992-03-19 | 1994-07-26 | Nippon Zeon Co Ltd | 日本脳炎ウイルス及びb型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス |
US6686147B1 (en) * | 1998-07-15 | 2004-02-03 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
PT1272633E (pt) * | 2000-03-30 | 2011-06-27 | Dendreon Corp | Composições e métodos para imunoterapia baseada em células dendríticas |
US20030044813A1 (en) * | 2001-03-30 | 2003-03-06 | Old Lloyd J. | Cancer-testis antigens |
EP1708741B1 (en) * | 2003-12-24 | 2016-03-30 | Aduro Biotech | Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof |
GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
NZ581306A (en) * | 2004-11-16 | 2011-03-31 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
EP2021017A2 (en) * | 2006-05-26 | 2009-02-11 | GlaxoSmithKline Biologicals S.A. | Method |
NZ578285A (en) * | 2007-01-15 | 2011-12-22 | Glaxosmithkline Biolog Sa | Fusion protein comprising a prame linked to a immunological fusion partner protein and additional amino acids at the n terminal end of the fusion partner sequence |
-
2008
- 2008-01-11 PL PL08727588T patent/PL2118128T3/pl unknown
- 2008-01-11 PE PE2008000128A patent/PE20081687A1/es not_active Application Discontinuation
- 2008-01-11 KR KR1020097016892A patent/KR20090122426A/ko not_active Application Discontinuation
- 2008-01-11 SI SI200830870T patent/SI2118128T1/sl unknown
- 2008-01-11 EP EP08727588A patent/EP2118128B1/en not_active Not-in-force
- 2008-01-11 EA EA200900738A patent/EA016818B1/ru not_active IP Right Cessation
- 2008-01-11 ES ES08727588T patent/ES2398492T3/es active Active
- 2008-01-11 JP JP2009545705A patent/JP2010532656A/ja active Pending
- 2008-01-11 DK DK08727588.9T patent/DK2118128T3/da active
- 2008-01-11 CA CA002674458A patent/CA2674458A1/en not_active Abandoned
- 2008-01-11 TW TW097101220A patent/TW200902049A/zh unknown
- 2008-01-11 MX MX2009007572A patent/MX2009007572A/es active IP Right Grant
- 2008-01-11 WO PCT/US2008/050879 patent/WO2008089074A2/en active Application Filing
- 2008-01-11 BR BRPI0806501-2A2A patent/BRPI0806501A2/pt not_active IP Right Cessation
-
2013
- 2013-01-14 HR HRP20130022AT patent/HRP20130022T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
MX2009007572A (es) | 2009-10-13 |
KR20090122426A (ko) | 2009-11-30 |
HRP20130022T1 (hr) | 2013-02-28 |
JP2010532656A (ja) | 2010-10-14 |
PL2118128T3 (pl) | 2013-03-29 |
EP2118128A2 (en) | 2009-11-18 |
DK2118128T3 (da) | 2013-02-18 |
EA200900738A1 (ru) | 2010-02-26 |
BRPI0806501A2 (pt) | 2014-04-22 |
EA016818B1 (ru) | 2012-07-30 |
SI2118128T1 (sl) | 2013-02-28 |
EP2118128B1 (en) | 2012-11-07 |
ES2398492T3 (es) | 2013-03-19 |
WO2008089074A9 (en) | 2012-07-12 |
WO2008089074A3 (en) | 2008-12-31 |
WO2008089074A2 (en) | 2008-07-24 |
TW200902049A (en) | 2009-01-16 |
CA2674458A1 (en) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081687A1 (es) | Proteina de fusion | |
CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
AR078423A1 (es) | Vacunas dirigidas a las celulas de langerhans | |
CO6382140A2 (es) | Composiciones de vacuna que comprenden una proteina de enlace del factor h mutada | |
BR112013027829A2 (pt) | anticorpos anti-cd40 e método de uso | |
BR112015017548A8 (pt) | construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit | |
GT201200271A (es) | Proteínas que se unen al tnf-a | |
BRPI0708344B8 (pt) | vetores adenovirais quiméricos e composição imunogênica | |
AR101669A1 (es) | Constructos de anticuerpos para cdh19 y cd3 | |
ECSP11011115A (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t | |
AR078778A1 (es) | Proteinas de union a antigenos de il-23 | |
BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
AR091649A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos | |
PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
EA201590545A1 (ru) | Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией | |
CL2012001966A1 (es) | Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis. | |
CO6351750A2 (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5 | |
WO2008121615A3 (en) | Antibody formulation | |
CR10555A (es) | Vacunas para malaria | |
AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
WO2014134561A3 (en) | Quantification of vaccine compositions | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
CO6460768A2 (es) | Anticuerpos específicos para dkk-1 y sus usos | |
MY192248A (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
CL2012003094A1 (es) | Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |